Brigatinib vs Ceritinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: ALK · full Non-Small Cell Lung Cancer pipeline
Brigatinib
Marketed by Takeda Pharmaceutical Company
NCT02737501 · Phase 3 · completed
This was a randomized, open-label active-controlled trial of 275 participants, with progression-free survival assessed by a blinded independent review committee as the primary clinical endpoint. The primary comparison favored brigatinib and was statistically significant, but the lack of participant and investigator blinding limits the strength of the evidence.
Next expected readout: November 2026 · NCT04223596 (registry estimate)
Reported efficacy
Progression-free Survival (PFS) as Assessed by Blinded Independent Review Committee (BIRC) Per RECIST v1.1 (Up to 33.8 months): Progression-free Survival (PFS) as Assessed by Blinded Independent Review Committee (BIRC) Per RECIST v1.1 (Up to 33.8 months): Brigatinib 19.253 months vs Alectinib 19.187 months (missed)
Result source: NCT03596866
Ceritinib
Marketed by Novartis
NCT01828099 · Phase 3 · completed
The trial was randomized and actively controlled, with 189 patients assigned to ceritinib and 187 to chemotherapy, but treatment was open-label rather than double-blind. Its clinical primary endpoint, progression-free survival assessed by an independent review committee, was met: median progression-free survival was 16.6 versus 8.1 months, with hazard ratio 0.55 (95% CI 0.42–0.73; p<0.001).
Next expected readout: December 2026 · NCT02321501 (registry estimate)
Reported efficacy
Progression Free Survival (PFS) by Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause, up to approximately 34 months): Progression Free Survival (PFS) by Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause, up to approximately 34 months): Ceritinib 16.6 Months (95% CI 12.6 to 27.2) vs Chemotherapy 8.1 Months (95% CI 5.8 to 11.1) (met)
Result source: NCT01828099
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
PFS, median
- Brigatinib
- 24.0 vs 11.1vs CrizotinibNCT02737501
10 other results
- 19.3 vs 19.2 NCT03596866
- 16.8 vs 16.6 NCT03596866
- 9.2 NCT02094573
- 15.6 NCT02094573
- 12.6 NCT01449461
- 11 NCT01449461
- 5.4 NCT01449461
- 5.4 NCT01449461
- 5.4 NCT01449461
- 1.8 NCT01449461
- Ceritinib
- 16.6 vs 8.1vs ChemotherapyNCT01828099
10 other results
- 5.4 vs 1.6 NCT01828112
- 16.8 vs 7.2 NCT01828099
- 6.2 vs 1.6 NCT01828112
- 5.8 NCT01685060
- 7.4 NCT01685060
- 15.2 NCT01283516
- 19.3 NCT01283516
- 7.2 NCT02040870
- 3.8 NCT02040870
- 3.7 NCT02450903
OS, median
- Brigatinib
- 25.9bNCT02094573
8 other results
- 40.6 NCT02094573
- 21.3 NCT03535740
- 11.6 NCT01449461
- 17.9 NCT01449461
- 8.3 NCT01449461
- 7.3 NCT01449461
- 7.3 NCT01449461
- 5.3 NCT01449461
- Ceritinib
- 62.9 vs 40.7vs ChemotherapyNCT01828099
5 other results
- 17.7 vs 20.1 NCT01828112
- 15.6 NCT01685060
- 51.3 NCT01685138
- 17.5 NCT02040870
- 17.3 NCT02450903
ORR
- Brigatinib
- 74.5% vs 62.3%vs CrizotinibNCT02737501
6 other results
- 45.5% NCT02094573
- 57.3% NCT02094573
- 26.2% NCT03535740
- 51.8% NCT02094573
- 56.4% NCT02094573
- 26.2% NCT03535740
- Ceritinib
- 72.5% vs 26.7%vs ChemotherapyNCT01828099
12 other results
- 73.5% vs 33.2% NCT01828099
- 40.9% vs 6.9% NCT01828112
- 44.3% vs 6.9% NCT01828112
- 40.7% NCT01685060
- 67.7% NCT01685138
- 25% NCT02450903
- 35.7% NCT01685060
- 73.5% NCT01283516
- 65.1% NCT01283516
- 63.7% NCT01685138
- 41.7% NCT02040870
- 32% NCT02040870
Duration of response, median
- Brigatinib
- 33.1 vs 13.8vs CrizotinibNCT02737501
2 other results
- 12 NCT02094573
- 13.8 NCT02094573
- Ceritinib
- 23.9 vs 11.1vs ChemotherapyNCT01828099
12 other results
- 22.6 vs 9.8 NCT01828099
- 7.6 vs 10.4 NCT01828112
- 6.7 vs 8.3 NCT01828112
- 10.6 NCT01685060
- 12.9 NCT01685060
- 14.2 NCT01283516
- 21.8 NCT01283516
- 24 NCT01685138
- 27.3 NCT01685138
- 7.5 NCT02040870
- 9.2 NCT02040870
- 6.3 NCT02450903
- b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
10 other shared endpoints and safety
Coverage. Brigatinib: 14 of 14 rows · Ceritinib: 14 of 14 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Brigatinib Rows use multiple source trials | Ceritinib Rows use multiple source trials |
|---|---|---|
| Disease Control responder rate · % of participants | 85.4% (n=137) vs 86.2% (n=138) Crizotinib90 mg QD/180 QDa,b NCT02737501 · Phase 3 · monotherapy · Advanced Solid Tumors, Non-Small Cell Lung Cancer · phase 3 | 84.7% (n=189) vs 73.8% (n=187) Chemotherapyc,a,b NCT01828099 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 1 more dose89.4% (n=189) vs 75.9% (n=187) Chemotherapy NCT01828099 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 |
| Disease Control responder rate · % of participants No placebo or comparator arm | 81.3% (n=112)90 mgc,a,d,b NCT02094573 · Phase 2 show 1 more dose86.4% (n=110)90 mg - 180 mg NCT02094573 · Phase 2 | 70% (n=20)a,d,b NCT02450903 · Phase 2 · registry result, not featured evidence 2 other source trials77.7% (n=103) NCT02040870 · Phase 1/2 · registry result, not featured evidence 67% (n=103) NCT02040870 · Phase 1/2 · registry result, not featured evidence |
| Duration of Response time to event · months No placebo or comparator arm | 12 months90 mgc,e,a,d,b NCT02094573 · Phase 2 show 1 more dose13.8 months90 mg - 180 mg NCT02094573 · Phase 2 | 14.19 monthsc,e,a,d,b NCT01283516 · Phase 1 show 1 more dose21.75 months NCT01283516 · Phase 1 |
| Intracranial Duration of Response time to event · months | 17.413 vs NA Alectinib monthsf,b NCT03596866 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 | 16.6 vs NA Chemotherapy monthsf,b NCT01828099 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 |
| Intracranial ORR responder rate · % of participants No placebo or comparator arm | 14.5% (n=55)90 mg/180 mg With Optional Dose Escalation to 240 mgg,d,b NCT03535740 · Phase 2 · registry result, not featured evidence | 0% (n=2)g,d,b NCT02450903 · Phase 2 · registry result, not featured evidence 6 other source trials20% (n=10) NCT01685138 · Phase 2 · registry result, not featured evidence 61.5% (n=13) NCT01685138 · Phase 2 · registry result, not featured evidence 45% (n=20) @ 24wk750 mg NCT01685060 · Phase 2 · registry result, not featured evidence 35.7% (n=28) @ 24wk750 mg NCT01685060 · Phase 2 · registry result, not featured evidence 39.1% (n=23) NCT02040870 · Phase 1/2 · registry result, not featured evidence 0% (n=9) NCT02040870 · Phase 1/2 · registry result, not featured evidence |
| ORR responder rate · % of participants No placebo or comparator arm | 45.5% (n=112)90 mgc,e,a,d,b NCT02094573 · Phase 2 show 3 more doses51.8% (n=112)90 mg NCT02094573 · Phase 2 57.3% (n=110)90 mg - 180 mg NCT02094573 · Phase 2 56.4% (n=110)90 mg - 180 mg NCT02094573 · Phase 2 | 73.5% (n=83)c,e,a,d,b NCT01283516 · Phase 1 show 1 more dose65.1% (n=83) NCT01283516 · Phase 1 |
| Overall Survival time to event · months No placebo or comparator arm | 25.9 months90 mgc,a,d,b NCT02094573 · Phase 2 show 1 more dose40.6 months90 mg - 180 mg NCT02094573 · Phase 2 | 17.3 monthsa,d,b NCT02450903 · Phase 2 · registry result, not featured evidence 3 other source trials51.3 months NCT01685138 · Phase 2 · registry result, not featured evidence 15.6 months @ 24wk750 mg NCT01685060 · Phase 2 · registry result, not featured evidence 17.5 months NCT02040870 · Phase 1/2 · registry result, not featured evidence |
| PFS time to event · months No placebo or comparator arm | 9.2 months90 mgc,e,a,d,b NCT02094573 · Phase 2 show 1 more dose15.6 months90 mg - 180 mg NCT02094573 · Phase 2 | 15.21 monthsc,e,a,d,b NCT01283516 · Phase 1 show 1 more dose19.32 months NCT01283516 · Phase 1 |
| Time to Response time to event · months | 1.84 vs 1.873 Crizotinib months90 mg QD/180 QDa,b NCT02737501 · Phase 3 · monotherapy · Advanced Solid Tumors, Non-Small Cell Lung Cancer · phase 3 | 1.42 vs 3.08 Chemotherapy months*c,a,b NCT01828099 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 · converted to months from 6.14 weeks as posted show 1 more dose1.45 vs 2.93 Chemotherapy months* NCT01828099 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 · converted to months from 6.29 weeks as posted |
| Time to Response time to event · months No placebo or comparator arm | 1.8 months90 mgc,a,d,b NCT02094573 · Phase 2 show 1 more dose1.9 months90 mg - 180 mg NCT02094573 · Phase 2 | 1.8 monthsa,d,b NCT02450903 · Phase 2 · registry result, not featured evidence 6 other source trials2.5 months NCT01685138 · Phase 2 · registry result, not featured evidence 2.2 months NCT01685138 · Phase 2 · registry result, not featured evidence 3 months @ 24wk750 mg NCT01685060 · Phase 2 · registry result, not featured evidence 2.2 months @ 24wk750 mg NCT01685060 · Phase 2 · registry result, not featured evidence 1.9 months NCT02040870 · Phase 1/2 · registry result, not featured evidence 1.8 months NCT02040870 · Phase 1/2 · registry result, not featured evidence |
| Dropout rate | 85.4%90 mg QD/180 QDh NCT02737501 · Phase 3 · monotherapy · Advanced Solid Tumors, Non-Small Cell Lung Cancer · phase 3 show 12 more results97.6% NCT03596866 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 n/a: no completion milestone90 mg NCT02094573 · Phase 2 n/a: no completion milestone90 mg - 180 mg NCT02094573 · Phase 2 —90/180 mg NCT03535740 · Phase 2 · registry result, not featured evidence —240 mg NCT03535740 · Phase 2 · registry result, not featured evidence n/a: no completion milestone90 mg/180 mg NCT03410108 · Phase 2 · registry result, not featured evidence n/a: no completion milestone90 mg QD NCT01449461 · Phase 1/2 · registry result, not featured evidence n/a: no completion milestone90 mg QD-180 mg QD NCT01449461 · Phase 1/2 · registry result, not featured evidence n/a: no completion milestone240 mg QD/120 mg BID/300 mg QD NCT01449461 · Phase 1/2 · registry result, not featured evidence n/a: no completion milestone180 mg QD/90 mg BID NCT01449461 · Phase 1/2 · registry result, not featured evidence n/a: no completion milestone120 mg QD/60 mg BID NCT01449461 · Phase 1/2 · registry result, not featured evidence n/a: no completion milestone30 mg QD/60 mg QD NCT01449461 · Phase 1/2 · registry result, not featured evidence | n/a: no completion milestonei NCT01828099 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 17 more resultsn/a: no completion milestoneCeritinib NCT01828112 · Phase 3 · monotherapy —Ceritinib (On-treatment) NCT01828112 · Phase 3 n/a: no completion milestone750 mg NCT01283516 · Phase 1 n/a: no completion milestone700 mg NCT01283516 · Phase 1 n/a: no completion milestone600 mg NCT01283516 · Phase 1 n/a: no completion milestone500 mg NCT01283516 · Phase 1 n/a: no completion milestone400 mg NCT01283516 · Phase 1 n/a: no completion milestone300 mg NCT01283516 · Phase 1 n/a: no completion milestone200 mg NCT01283516 · Phase 1 n/a: no completion milestone100 mg NCT01283516 · Phase 1 n/a: no completion milestone50 mg NCT01283516 · Phase 1 n/a: no completion milestone NCT02450903 · Phase 2 · registry result, not featured evidence 74.2%LDK378 (Ceritinib) NCT01685138 · Phase 2 · registry result, not featured evidence —LDK378 Ceritinib) NCT01685138 · Phase 2 · registry result, not featured evidence —750 mg NCT01685060 · Phase 2 · registry result, not featured evidence n/a: no completion milestone750 mg NCT01685060 · Phase 2 · registry result, not featured evidence n/a: no completion milestone NCT02040870 · Phase 1/2 · registry result, not featured evidence |
| Discontinued due to AEs | —90 mg QD/180 QDh NCT02737501 · Phase 3 · monotherapy · Advanced Solid Tumors, Non-Small Cell Lung Cancer · phase 3 show 12 more results— NCT03596866 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 3.6%90 mg NCT02094573 · Phase 2 12.7%90 mg - 180 mg NCT02094573 · Phase 2 —90/180 mg NCT03535740 · Phase 2 · registry result, not featured evidence —240 mg NCT03535740 · Phase 2 · registry result, not featured evidence 3.8%90 mg/180 mg NCT03410108 · Phase 2 · registry result, not featured evidence 16.7%90 mg QD NCT01449461 · Phase 1/2 · registry result, not featured evidence 9.4%90 mg QD-180 mg QD NCT01449461 · Phase 1/2 · registry result, not featured evidence 26.7%240 mg QD/120 mg BID/300 mg QD NCT01449461 · Phase 1/2 · registry result, not featured evidence 8.3%180 mg QD/90 mg BID NCT01449461 · Phase 1/2 · registry result, not featured evidence 11.1%120 mg QD/60 mg BID NCT01449461 · Phase 1/2 · registry result, not featured evidence 0%30 mg QD/60 mg QD NCT01449461 · Phase 1/2 · registry result, not featured evidence | 12.7%i NCT01828099 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 17 more results6.1%Ceritinib NCT01828112 · Phase 3 · monotherapy —Ceritinib (On-treatment) NCT01828112 · Phase 3 11%750 mg NCT01283516 · Phase 1 0%700 mg NCT01283516 · Phase 1 20%600 mg NCT01283516 · Phase 1 0%500 mg NCT01283516 · Phase 1 0%400 mg NCT01283516 · Phase 1 0%300 mg NCT01283516 · Phase 1 0%200 mg NCT01283516 · Phase 1 0%100 mg NCT01283516 · Phase 1 0%50 mg NCT01283516 · Phase 1 15% NCT02450903 · Phase 2 · registry result, not featured evidence 14.5%LDK378 (Ceritinib) NCT01685138 · Phase 2 · registry result, not featured evidence —LDK378 Ceritinib) NCT01685138 · Phase 2 · registry result, not featured evidence —750 mg NCT01685060 · Phase 2 · registry result, not featured evidence 8.6%750 mg NCT01685060 · Phase 2 · registry result, not featured evidence 6.8% NCT02040870 · Phase 1/2 · registry result, not featured evidence |
| Serious AEs | 41.2%90 mg QD/180 QDh NCT02737501 · Phase 3 · monotherapy · Advanced Solid Tumors, Non-Small Cell Lung Cancer · phase 3 show 12 more results30.4% NCT03596866 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 53.2%90 mg NCT02094573 · Phase 2 62.7%90 mg - 180 mg NCT02094573 · Phase 2 46.6%90/180 mg NCT03535740 · Phase 2 · registry result, not featured evidence 23.1%240 mg NCT03535740 · Phase 2 · registry result, not featured evidence 35.6%90 mg/180 mg NCT03410108 · Phase 2 · registry result, not featured evidence 55.6%90 mg QD NCT01449461 · Phase 1/2 · registry result, not featured evidence 43.8%90 mg QD-180 mg QD NCT01449461 · Phase 1/2 · registry result, not featured evidence 73.3%240 mg QD/120 mg BID/300 mg QD NCT01449461 · Phase 1/2 · registry result, not featured evidence 62.5%180 mg QD/90 mg BID NCT01449461 · Phase 1/2 · registry result, not featured evidence 55.6%120 mg QD/60 mg BID NCT01449461 · Phase 1/2 · registry result, not featured evidence 16.7%30 mg QD/60 mg QD NCT01449461 · Phase 1/2 · registry result, not featured evidence | 49.2%i NCT01828099 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 17 more results—Ceritinib NCT01828112 · Phase 3 · monotherapy 49.6%Ceritinib (On-treatment) NCT01828112 · Phase 3 56.9%750 mg NCT01283516 · Phase 1 60%700 mg NCT01283516 · Phase 1 70%600 mg NCT01283516 · Phase 1 40%500 mg NCT01283516 · Phase 1 50%400 mg NCT01283516 · Phase 1 33.3%300 mg NCT01283516 · Phase 1 33.3%200 mg NCT01283516 · Phase 1 50%100 mg NCT01283516 · Phase 1 0%50 mg NCT01283516 · Phase 1 45% NCT02450903 · Phase 2 · registry result, not featured evidence —LDK378 (Ceritinib) NCT01685138 · Phase 2 · registry result, not featured evidence 40.3%LDK378 Ceritinib) NCT01685138 · Phase 2 · registry result, not featured evidence 47.9%750 mg NCT01685060 · Phase 2 · registry result, not featured evidence —750 mg NCT01685060 · Phase 2 · registry result, not featured evidence 35% NCT02040870 · Phase 1/2 · registry result, not featured evidence |
| Most frequent reported AEs | 90 mg QD/180 QDh diarrhoea 57.4% blood creatine phosphokinase increased 50% cough 36% NCT02737501 · Phase 3 · monotherapy · Advanced Solid Tumors, Non-Small Cell Lung Cancer · phase 3 show 12 more resultsblood creatine phosphokinase increased 73.6% aspartate aminotransferase increased 56.8% alanine aminotransferase increased 47.2% NCT03596866 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 90/180 mg diarrhoea 39.8% blood creatine phosphokinase increased 34% nausea 28.2% NCT03535740 · Phase 2 · registry result, not featured evidence 240 mg diarrhoea 53.8% blood creatine phosphokinase increased 38.5% aspartate aminotransferase increased 23.1% NCT03535740 · Phase 2 · registry result, not featured evidence 90 mg/180 mg blood creatine phosphokinase increased 77.9% hypertension 47.1% diarrhoea 45.2% NCT03410108 · Phase 2 · registry result, not featured evidence 90 mg QD fatigue 50% diarrhoea 44.4% headache 44.4% NCT01449461 · Phase 1/2 · registry result, not featured evidence 90 mg QD-180 mg QD diarrhoea 53.1% fatigue 50% nausea 50% NCT01449461 · Phase 1/2 · registry result, not featured evidence 240 mg QD/120 mg BID/300 mg QD fatigue 80% cough 53.3% diarrhoea 53.3% NCT01449461 · Phase 1/2 · registry result, not featured evidence 180 mg QD/90 mg BID nausea 68.8% diarrhoea 43.8% fatigue 39.6% NCT01449461 · Phase 1/2 · registry result, not featured evidence 120 mg QD/60 mg BID fatigue 50% nausea 50% aspartate aminotransferase increased 38.9% NCT01449461 · Phase 1/2 · registry result, not featured evidence 30 mg QD/60 mg QD abdominal pain 50% nausea 50% electrocardiogram qt prolonged 33.3% NCT01449461 · Phase 1/2 · registry result, not featured evidence | i diarrhoea 84.7% nausea 68.8% vomiting 67.2% NCT01828099 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 14 more resultsdiarrhoea 85.5% nausea 78.2% vomiting 71.8% NCT01685138 · Phase 2 · registry result, not featured evidence 750 mg diarrhoea 82.1% nausea 82.1% vomiting 65.7% NCT01685060 · Phase 2 · registry result, not featured evidence diarrhoea 74.8% vomiting 61.2% alanine aminotransferase increased 59.2% NCT02040870 · Phase 1/2 · registry result, not featured evidence |
Notes
- aPopulation context differs: registered conditions differ.
- bThe assessment timepoint is not available for both results.
- cThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- dTreatment context has not been resolved for both arms.
- eTrial phases differ: Phase 1 versus Phase 2.
- fPopulation context differs: prior_therapy differs (naive versus experienced).
- gPopulation comparability has not been reviewed for both studies.
- hPopulation comparability has not been reviewed for 11 of these studies.
- iPopulation comparability has not been reviewed for 17 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Brigatinib
show 1 more result
show 3 more results
show 3 more results
show 7 more results
+ 6 further endpoints in the CSV export.
Ceritinib
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Brigatinib's landscape · Ceritinib's landscape